Equities Analysts Issue Forecasts for Qiagen FY2025 Earnings

Key Points

• Analysts at Zacks Research have raised their FY2025 earnings per share estimate for Qiagen to $2.33, slightly up from the previous estimate of $2.32.
• Qiagen recently reported a quarterly earnings per share of $0.55, exceeding analysts' expectations of $0.50, with revenue of $483.46 million, a year-over-year increase of 5.2%.
• The stock currently has a consensus rating of "Hold" among analysts, with an average target price of $49.40.

Qiagen N.V. (NYSE:QGEN - Free Report) - Analysts at Zacks Research boosted their FY2025 earnings per share estimates for shares of Qiagen in a research note issued on Tuesday, July 22nd. Zacks Research analyst R. Department now anticipates that the company will post earnings of $2.33 per share for the year, up from their prior estimate of $2.32. The consensus estimate for Qiagen's current full-year earnings is $2.26 per share. Zacks Research also issued estimates for Qiagen's FY2027 earnings at $2.71 EPS.

Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.55 EPS for the quarter, topping the consensus estimate of $0.50 by $0.05. The company had revenue of $483.46 million during the quarter, compared to the consensus estimate of $465.66 million. Qiagen had a return on equity of 14.61% and a net margin of 4.68%. Qiagen's revenue for the quarter was up 5.2% on a year-over-year basis. During the same period last year, the company earned $0.44 EPS.

A number of other brokerages have also recently weighed in on QGEN. Redburn Atlantic lowered shares of Qiagen from a "buy" rating to a "neutral" rating in a research note on Friday, April 4th. Barclays initiated coverage on shares of Qiagen in a research note on Tuesday, June 24th. They set an "overweight" rating and a $55.00 target price on the stock. Bank of America raised their target price on shares of Qiagen from $50.00 to $53.00 and gave the company a "buy" rating in a research note on Thursday, June 26th. Wall Street Zen cut Qiagen from a "strong-buy" rating to a "buy" rating in a research report on Saturday. Finally, Robert W. Baird lifted their target price on Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a report on Monday, April 21st. Seven equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $49.40.

Qiagen Stock Up 0.3%

NYSE:QGEN traded up $0.14 during mid-day trading on Friday, hitting $51.12. The stock had a trading volume of 364,369 shares, compared to its average volume of 1,368,353. The stock has a 50-day simple moving average of $46.91 and a two-hundred day simple moving average of $43.25. Qiagen has a twelve month low of $37.63 and a twelve month high of $51.88. The company has a current ratio of 3.37, a quick ratio of 2.83 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $11.36 billion, a PE ratio of 128.16, a PEG ratio of 2.63 and a beta of 0.68.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. SVB Wealth LLC acquired a new stake in shares of Qiagen during the first quarter valued at about $31,000. Brown Brothers Harriman & Co. acquired a new stake in Qiagen during the 4th quarter worth approximately $37,000. Farther Finance Advisors LLC lifted its holdings in shares of Qiagen by 400.5% during the second quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company's stock worth $51,000 after purchasing an additional 849 shares during the period. Hilltop National Bank acquired a new position in shares of Qiagen during the second quarter worth $66,000. Finally, ANTIPODES PARTNERS Ltd acquired a new position in shares of Qiagen in the 1st quarter valued at about $94,000. Institutional investors and hedge funds own 70.00% of the company's stock.

Qiagen Announces Dividend

The firm also recently declared a dividend, which was paid on Thursday, July 10th. Shareholders of record on Thursday, July 3rd were paid a dividend of $0.25 per share. The ex-dividend date was Wednesday, July 2nd. This represents a yield of 0.52%. Qiagen's dividend payout ratio is currently 62.50%.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.